Terbinafine-induced subacute cutaneous lupus erythematosus

被引:20
作者
Farhi, D
Viguier, M
Cosnes, A
Reygagne, P
Dubertret, L
Revuz, J
Roujeau, JC
Bachelez, H
机构
[1] Hop St Louis, Dept Dermatol 1, FR-75475 Paris, France
[2] Hop Henri Mondor, Dept Dermatol, F-94010 Creteil, France
关键词
subacute lupus erythematosus; terbinafine; cutaneous drug reaction;
D O I
10.1159/000089024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Background: Nearly 10% of lupus erythematosus ( LE) are drug induced. More than 60 different drugs are involved in iatrogenic LE. We report herein 3 cases of terbinafine-induced LE. Observations: Three patients receiving terbinafine for a suspected dermatophytic infection developed a subacute cutaneous LE, within 7 weeks following terbinafine introduction. The patients' medical history included sicca syndrome, lung carcinoma and Kikuchi disease, respectively. Clinical remission occurred within 15 weeks following terbinafine withdrawal. Discussion: Sixteen cases of terbinafine-induced LE have been previously reported, including 13 women. The median age was 54 years. Prior autoimmunity was reported in 10 cases, including 5 pre-existing LE. The median delay between terbinafine introduction and LE onset was 5 weeks. The median time until clinical recovery following terbinafine withdrawal was 8 weeks. Conclusion: Terbinafine should be prescribed only in patients with proven dermatophytosis. We recommend cautious monitoring in patients with pre-existing autoimmunity. The diagnosis of terbinafine-induced LE should lead to the immediate and definitive withdrawal of the drug. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 34 条
[1]
DRUG-RELATED LUPUS - INCIDENCE, MECHANISMS AND CLINICAL IMPLICATIONS [J].
ADAMS, LE ;
HESS, EV .
DRUG SAFETY, 1991, 6 (06) :431-449
[2]
Oral terbinafine-induced bullous pemphigoid [J].
Aksakal, BA ;
Özsoy, E ;
Arnavut, Ö ;
Gürer, MA .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (11) :1625-1627
[3]
Atzeni F, 2003, Reumatismo, V55, P147
[4]
Terbinafine-induced subacute cutaneous lupus erythematosus [J].
Bonsmann, G ;
Schiller, M ;
Luger, TA ;
Ständer, S .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (06) :925-931
[5]
Brooke R, 1998, BRIT J DERMATOL, V139, P1132, DOI 10.1046/j.1365-2133.1998.2576q.x
[6]
Callen JP, 2001, ARCH DERMATOL, V137, P1196
[7]
CARSTENS J, 1994, ACTA DERM-VENEREOL, V74, P391
[8]
Condon CA, 1998, BRIT J DERMATOL, V138, P709, DOI 10.1046/j.1365-2133.1998.02195.x
[9]
FAERGEMANN J, 1993, ACTA DERM-VENEREOL, V73, P305
[10]
Is systemic autoimmune disease a risk factor for terbinafine-induced erythema multiforme? [J].
Goeteyn, V ;
Naeyaert, JM ;
Lambert, J ;
Monbaliu, L ;
Vermander, F .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (03) :578-579